Yabao's Generic Sorafenib Tosylate Receives Approval in the U.S.
New Delhi, Beijing, April 27, 2022: Global pharma major Lupin Limited (Lupin) today announced that it has entered into a strategic partnership with Yabao Pharmaceutical Co. Inc. (Yabao), to meet the growing demand for quality drugs with pediatric formulations in the Chinese markets.
Global pharma major Lupin Limited (Lupin) has entered into a strategic partnership with Yabao Pharmaceutical Co. Inc. (Yabao), to meet the growing demand for quality drugs with paediatric formulations in the Chinese markets.
YABAO PHARM`s generic SORAFENIB TOSYLATE Receives Tentative Approval in US
China's Yabao Pharmaceutical and the University of South Australia have finalized a partnership first announced in September to create a drug discovery laboratory to develop cancer drugs.
China's WuXi PharmaTech ($WX) and U.S.-based Eli Lilly ($LLY) plan to develop a candidate to lower cardiovascular risk in patients with dyslipidemia in China that will see the local firm carry the load on development, regulatory approval and manufacturing, while the Indianapolis-headquartered multinational focuses on sales and marketing.
Yabao Pharmaceuticals and the University of South Australia would build a co-funded laboratory where drug candidates would be identified by the university. The laboratory is where new cancer treatments would be developed.